Bellmunt J, de Wit R, Fradet Y, Climent MA, et al. Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clin Cancer Res 2022;28:2050-2060.
PMID: 35247908